First-in-Class Takeda, Protagonist Drug Lands FDA Approval in Rare Blood Disorder
Takeda Pharmaceutical’s Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with limited therapeutic options. Originally developed by Protagonist Therapeutics, the engineered peptide gives Takeda a drug with blockbuster sales potential as the pharma company’s top overall product faces patent expirations.
AI Won’t Transform Health Systems, CEOs Will — 6 Principles to Drive the Transformation
If AI is not one of the CEO’s top two or three priorities, the organization will produce pilots and slide decks while better-mobilized peers pull ahead and the institution’s ability to fulfill its mission erodes
Hospitals Are All In on AI, but Testing and Oversight Haven’t Caught Up
A new report found that while more than 90% of health systems have deployed third-party AI tools, less than half have the infrastructure to properly test and validate them before they become embedded in patient care.
SK Bio Broadens U.S. Prospects, Licensing Late-Stage Epilepsy Drug From Biohaven
Biohaven is outlicensing to SK Biopharmaceuticals global rights to opakalim, a Kv7-targeting small molecule in pivotal clinical testing for epilepsy. Biohaven gets non-dilutive financing for its pipeline while SK Bio gains another asset to potentially commercialize in the U.S.
The Missing Piece in Lowering the Cost of Care: Predictability
When the healthcare system defaults to uncertainty, people delay care because it feels safer for their wallets. In some cases, people wait too long, leaving an ER visit as the path of least resistance.